EFFECTS OF DAPA/ EMPA ON SERUM URIC ACID LEVELS IN HOSPITALIZED TYPE 2 DIABETES MELLITUS PATIENTS

Abstract

Background: Metabolic disorders like hyperuricemia have been long associated with Diabetes mellitus and are found to be associated with DM in very complex manners.

Objectives: To observe whether Sodium-Glucose Transporter 2 Inhibitors decrease serum uric acid levels in patients with type 2 diabetes mellitus

Methods: This prospective observational study was conducted at the Medicine Department of Pak Emirates Military Hospital, Rawalpindi. The patients were divided into two Groups: one Group received a Sodium-Glucose Transporter 2 Inhibitor (Group S), and the other Group continued their routine oral anti-hyperglycaemic treatment (Group D). Group S received empagliflozin 10-25 mg daily, whereas Group D received metformin and glimepiride alone or in combination to maintain a fasting blood sugar <110 mg/dl. The primary parameter observed at the end of four weeks post-medication was the difference in uric levels between Groups.

Results: Mean age of patients was 47.77±4.67 years in Group S versus 47.43±4.64 years in Group D (p=0.016). Levels of serum uric acid in Group S were 7.81±0.72 mg/dl before and 6.46±0.57 mg/dl at the end of the study (p=0.001). In Group D, levels of serum uric acid were 8.10±0.75 mg/dl before and 8.05±0.68 mg/dl at the end of the study (p=0.167). The difference was statistically higher in Group S when compared to Group D, in which no statistically significant difference was observed.

Conclusion: Sodium-Glucose Transporter 2 Inhibitors significantly decrease serum uric levels while also modestly decreasing body weight and body mass index.